Current status and fluconazole treatment of pelvic fungal gynecological infections

Chemotherapy

Volumn 46, Issue 3, 2000, Pages 209-212

  Mikamo, Hiroshige ^a   Sato, Yasumasa ^a   Hayasaki, Yoh ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Candida glabrata; Fluconazole; Systemic fungal infection

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FLUCONAZOLE; LACTATE DEHYDROGENASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASCITES FLUID; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FUNGUS CULTURE; HUMAN; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; MYCOSIS; PELVIC INFLAMMATORY DISEASE; PERITONITIS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0034074774     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007281     Document Type: Article

References (15)

1. Kramer KM, Skaar DJ, Ackerman BH: The fluconazole era: Management of hematogenously disseminated candidiasis in the nonneutropenic patient. Pharmacotherapy 1997;17:538-548.
2. Rubin RH: Fungal and bacterial infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 1993;12(suppl 1):42-48.
3. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL: Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am J Med 1989;87:614-620.
4. Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A: Risk factors for candidemia in cancer patients: A case-control study. Clin Infect Dis 1988;26:429-432.
5. Swerdloff JN, Filler SG, Edwards JE Jr: Severe candidal infections in neutropenic patients. Clin Infect Dis 1993;7(suppl 2):S457-S467.
6. Walsh TJ, Hiemenz JW, Anaissie E: Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996;10: 365-400.
7. Uzun O, Anaissie EJ: Problems and controversies in the management of hematogenous candidiasis. Clin Infect Dis 1996;22(suppl 2):S95-S101.
8. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12(suppl 3):S318-S326.
9. Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL: Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429-2435.
10. Kujath P, Lerch K, Kochendorfer P, Boos C: Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993;21:376-382.
11. Rex JH, Bennett JE, Sugar AM, et al: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330.
12. Meunier F, Aoun M, Bitar N: Candidemia in immunocompromised patients. Clin Infect Dis 1992; 14(suppl 1):S120-S125.
13. van't Wout JW: Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis 1996;15:238-242.
14. Mikamo H, Kawazoe K, Sato Y, Hayasaki Y, Tamaya T: Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis. Chemotherapy 1998;44:364-368.
15. Mikamo H, Kawazoe K, Sato Y, Izumi K, Tamaya T: Pelvic abscess and fungemia caused by Candida glabrata. J Infect Chemother 1996; 2:294-296.